We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
Read moreWe've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...
Read moreWebinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...
Read moreThis article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read moreThis article explores the significant disparities between the US and Europe regarding orphan drugs a...
Read moreWe explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreThis is the first time that HAS is issuing a favorable opinion for the reimbursement of a technology...
Read moreWe summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...
Read moreThe German government has released information regarding the 20% discounts to combination products e...
Read more